|
|
CCL5 adjuvant |
|
Vaxjo ID |
369 |
|
Vaccine Adjuvant Name |
CCL5 adjuvant |
|
Alternative Names |
RANTES |
|
Adjuvant VO ID |
VO_0005543
|
|
Description |
natural chemokine adjuvant that induces Th1 response |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
chemokine ligand 5 (CCL5) |
|
Function |
CCL5 can induce anti-tumor immune responses leading to tumor eradication, by recruiting to the tumor site immune cells, such as CD4+ and CD8+ T cells, NK cells, and DCs |
|
Safety |
CCL5 plays a role in carcinogenesis and invasiveness of tumor cells |
| References |
Lapteva and Huang, 2010: Lapteva N, Huang XF. CCL5 as an adjuvant for cancer immunotherapy. Expert opinion on biological therapy. 2010; 10(5); 725-733. [PubMed: 20233026].
|
|
